Heart Disease Treatment: What Actually Works, According to the Research

Medications That Move the Needle

Statins remain the most studied heart disease treatment in modern medicine. A systematic review of 19 trials covering more than 71,000 people without prior cardiovascular events found that statin therapy reduced all-cause mortality by 14%, cardiovascular mortality by 31%, heart attacks by 36%, and strokes by 29%. Those are primary prevention numbers, meaning people who hadn't yet had an event.

For people who already have heart disease, the benefits are even more pronounced. A pooled analysis of over 186,000 participants across 28 trials showed a 21% reduction in major vascular events for every 1.0 mmol/L drop in LDL cholesterol. That benefit held across all age groups, though there's less direct evidence for patients over 75 who don't already have vascular disease.

Dose matters, too. High-dose statin therapy outperformed standard dosing in a meta-analysis of about 27,500 patients, producing a 16% additional reduction in coronary death or heart attack compared to moderate doses.

Beyond statins, two newer drug classes have changed the treatment landscape for patients who also have type 2 diabetes. GLP-1 receptor agonists and SGLT2 inhibitors both reduce major cardiovascular events by about 14% in diabetic patients with established cardiovascular disease. They work through different mechanisms, though. SGLT2 inhibitors cut heart failure hospitalizations by 31%, while GLP-1 agonists had a stronger effect on stroke prevention.

Metformin deserves a mention here as well. In patients with coronary artery disease, metformin reduced cardiovascular mortality by 19%, all-cause mortality by 33%, and cardiovascular events by 17% across a pooled analysis of over one million patients.

Surgery and Stents: When Do They Actually Help?

This is where the evidence gets counterintuitive.

For people with stable heart disease and even moderate-to-severe blockages, adding stents or bypass surgery to good medical therapy doesn't reduce death or heart attacks. The ISCHEMIA trial, which randomized 5,179 patients with stable coronary disease and documented ischemia, found no significant difference in cardiovascular death or heart attack between invasive and conservative strategies over a median of 3.2 years.

That's a hard finding for many patients to accept. But it's been replicated and is now reflected in clinical guidelines.

The picture changes for more complex disease. When three or more arteries are severely blocked, or when the left main coronary artery is involved, bypass surgery (CABG) outperforms stents. The SYNTAX trial, which randomized 1,800 patients with severe multi-vessel disease, found that CABG resulted in lower rates of major cardiac events at one year. The NOBLE trial confirmed this for left main disease specifically, with five-year event rates of 19% after surgery versus 29% after stents.

So the takeaway is nuanced. Stable blockages generally don't need opening. Complex blockages with certain anatomical patterns do, and surgery usually beats stents in those cases.

Diet: The Mediterranean Advantage

If there's one dietary pattern with robust evidence for heart disease, it's the Mediterranean diet.

The CORDIOPREV trial randomized 1,002 patients with established coronary heart disease to either a Mediterranean diet or a low-fat diet and followed them for seven years. The Mediterranean group had about 25-28% fewer major cardiovascular events. That's a secondary prevention trial, meaning these patients already had heart disease, and changing their diet still made a measurable difference.

A comprehensive review of 45 prospective studies, including the landmark PREDIMED trial, concluded that the evidence linking the Mediterranean diet to cardiovascular benefit is "large, strong, and consistent," with clinically meaningful reductions in coronary heart disease, stroke, and total cardiovascular disease.

The Mediterranean diet also outperforms low-fat diets for modifying cardiovascular risk factors like blood pressure, total cholesterol, and inflammatory markers.

What does this look like in practice? More olive oil, nuts, fish, vegetables, legumes, and whole grains. Less processed food, red meat, and refined carbohydrates. It's not a radical overhaul for most people.

Exercise and Cardiac Rehabilitation

Cardiac rehab is one of the most underused treatments in cardiology.

A meta-analysis of 85 trials involving over 23,000 participants found that exercise-based cardiac rehabilitation significantly reduced cardiovascular mortality, hospitalizations (by 23%), and heart attacks (by 18%). It also improved quality of life and was cost-effective.

Even in the modern era of stents and statins, cardiac rehabilitation after a heart attack or bypass surgery is associated with a 36-63% reduction in mortality. The benefit persists regardless of the specific rehab program design or delivery model.

The PREDIMED-Plus trial showed that combining a Mediterranean diet with structured physical activity and behavioral support produced meaningful improvements in weight, blood sugar, triglycerides, and inflammatory markers in overweight adults with metabolic syndrome.

The Genetics Factor

One emerging area is using genetic risk to guide treatment intensity.

People in the highest genetic risk category for coronary heart disease get roughly three times the benefit from statin therapy compared to those at low genetic risk. Across three primary prevention trials, the number needed to treat to prevent one coronary heart disease event over 10 years dropped from 57-66 in low-risk individuals to just 20-25 in the high-risk group.

This doesn't mean everyone needs genetic testing before starting a statin. But it does suggest that for borderline cases, where the decision to treat is genuinely uncertain, knowing your genetic risk could tip the balance.

What About Lipoprotein(a)?

Genetics also shapes risk through a marker most people have never heard of. Standard cholesterol panels don't measure lipoprotein(a), or Lp(a), but they probably should. An individual patient data meta-analysis of over 29,000 statin-treated patients found that elevated Lp(a) independently predicted cardiovascular events even after controlling for LDL cholesterol and other risk factors.

Statins don't lower Lp(a). So people with high Lp(a) carry residual risk that standard treatment doesn't address. Knowing your Lp(a) level helps you and your doctor understand whether your current treatment plan has blind spots.

Knowing Your Numbers

Heart disease treatment isn't one-size-fits-all, and the right approach depends on knowing where you actually stand. Beyond a standard cholesterol panel, markers like ApoB, Lp(a), and hs-CRP can reveal risk that basic tests miss.

The Advanced Heart Health Panel from Instalab costs $77 and measures these markers alongside a full lipid panel. No referral needed, and results come back in a few days.

Putting It All Together

The evidence points to a layered approach. Medications, particularly statins, form the foundation. Diet and exercise are not optional extras but genuine treatments with hard outcome data behind them.

Surgery has a narrow but important role for specific anatomical patterns. And newer medications like SGLT2 inhibitors and GLP-1 agonists are changing the game for patients with diabetes.

The most important thing is that treatment decisions be based on your individual risk profile, not just on whether you have a blockage or an abnormal cholesterol number.